KC Pharmaceuticals
Tracked across 14 events · 102 articles · First seen May 07, 2025 · Last active Jun 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Impact: KC Pharmaceuticals is facing a class action lawsuit for allegedly issuing materially false and/or misleading statements regarding its business operations and prospects, leading to artificial inflation of its stock price.
May 08, 2025 · 6 articles
Regulatory
Impact: KC Pharmaceuticals, Inc. is facing a federal securities class action lawsuit for allegedly making false and misleading statements, which led to a significant drop in its stock price.
May 16, 2025 · 6 articles
Business
Impact: KC Pharmaceuticals is the defendant in a class action lawsuit, accused of making false and misleading statements regarding its business operations and prospects, which could lead to significant financial liabilities and reputational damage.
May 14, 2025 · 6 articles
Business
Impact: KC Pharmaceuticals is facing a class action lawsuit for allegedly making false and misleading statements regarding its business operations and prospects, leading to investor losses.
May 08, 2025 · 6 articles
Regulatory
Impact: The KC Pharmaceuticals issued new advice warning against prolonged use of nasal decongestant sprays.
Jan 08, 2026 · 6 articles
Business
KC Pharmaceuticals, a biopharmaceutical company specializing in central nervous system diseases, announced its management will participate in two investor conferences in June 2026. These include the 2026 Jefferies Global Healthcare Conference on June 3, 2026,…
Impact: KC Pharmaceuticals will participate in two investor conferences in June 2026, providing an opportunity to engage with investors and potentially increase visibility and investor interest in the company.
May 27, 2026 · 6 articles
Domestic
Impact: KC Pharmaceuticals accepted the resignation of its finance head, Rajkumar Bafna, due to India — Delhi's air pollution, highlighting potential challenges in retaining talent in affected regions.
Dec 28, 2025 · 11 articles
Business
The global pre-filled syringe market is experiencing substantial growth, with projections indicating a rise from approximately US$ 4,698 million in 2025 to US$ 5,700 million by 2032, and from USD 8.65 billion in 2026 to…
Impact: KC Pharmaceuticals>>> is a key company in the pre-filled syringe market, contributing to its expansion.
May 25, 2026 · 6 articles
Business
Impact: KC Pharmaceuticals is one of the publicly traded companies presenting at the conference, seeking to attract investors and showcase its innovations.
Apr 02, 2026 · 7 articles
Domestic
Impact: Professor Claire Anderson, president of the KC Pharmaceuticals, affirms the safety of paracetamol use during pregnancy, citing extensive safe use and recent studies.
Sep 22, 2025 · 7 articles
News
Impact: KC Pharmaceuticals is under investigation for allegedly failing to disclose significant and ongoing destocking across its high-margin High-Value Products portfolio and operational inefficiencies with its SmartDose device, leading to weak revenue and earnings forecasts.
May 07, 2025 · 16 articles
Business
Impact: KC Pharmaceuticals is a majority-owned subsidiary of Lobe Sciences and is mentioned as part of Lobe's strategic development, though not directly impacted by this specific private placement.
Apr 11, 2026 · 7 articles
Business
Impact: Adamas Pharmaceuticals>>> was sold to KC Pharmaceuticals>>>.
May 19, 2026 · 6 articles
100
KC Pharmaceuticals will presentSupernus Pharmaceuticals...
NEWSDESK
Track KC Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard